

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Huvepharma, Inc.
USDA Vet Biologics Establishment Number	605
Product Code	19A5.D3
True Name	Swine Influenza Vaccine, DNA
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	ExactVac DNA - No distributor specified
Date of Compilation Summary	March 23, 2020

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

605 19A5.D3 Page 1 of 4

Study Type	Efficacy							
Pertaining to	•	enza virus						
Study Purpose	Swine influenza virus Efficacy against H3N2 influenza							
Product	Two doses administered intramuscularly two weeks apart							
Administration	I wo doses administered intramuscularly two weeks apart							
Study Animals	Commercial pigs 3 weaks of age 12 vaccinates and 15 controls							
Challenge Description	Commercial pigs, 3 weeks of age, 13 vaccinates and 15 controls Swine influenza virus A/swine/SouthDakota/A01280095/2103							
Chancinge Description	(H3N2) given 23 days after the final vaccination							
Interval observed	Lungs evaluated 5 days after challenge							
after challenge	Lungs evaluated 3 days after challenge							
Results	The percent of lung mass that was abnormal (consolidated) was calculated for each animal. Five tier summary of lung lesions							
	Group	mmary or run	Min	Q1	Med	Q3	Max	
	Vaccinate		0.00	0.45	1.45	2.74	8.61	
	Control		0.60	4.45	6.39	12.05	13.95	
	Lung conso	Vaccinates						
		0.00	0.60					
		0.00	0.90					
		0.05	2.65					
		0.45	4.19					
		0.60	4.70					
		1.38	5.65					
		1.45	6.29					
		1.50	6.39					
		2.20	1	5.04				
		2.74	1	0.94	_			
		2.90		1.81	4			
		7.13		2.29	_			
		8.61	1	2.95	_			
				3.56	\dashv			
			13.95					
USDA Approval Date	December 2	8, 2017						

605 19A5.D3 Page 2 of 4

Study Type	Safety							
Study Type Portaining to								
Pertaining to	All							
Study Purpose Product Administration	Demonstrate safety of product under typical use conditions.							
	Two doses administered intramuscularly two weeks apart.							
Study Animals	672 pigs at 3 sites. Minimum age 3 weeks.							
Challenge Description	Not applicable							
Interval observed after	Not applicable							
challenge	D: 1 1: 1: 4: 6: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1:							
Results	Pigs were observed immediately after vaccination and weekly							
	for three weeks after each vaccination.							
	Injection Site Reactions							
	Site	Total		imum si		Not Palpable	No	
		number		injection site			injection	
		animals	rea	ction (c	m)		site	
						4	reaction	
			< 1.5	1.5 –	> 5.0			
			1.5	5.0	> 5.0			
	Site 1	202	0	0	0	0	202	
	Site 2	228	9	0	0	1	218	
	Site 3	242	2	0	0	0	240	
	Injection site reactions were all resolved by 21 days after							
	vaccinat	ion.						
	Adverse Events							
	Number of clinical observations							
				post-vaccination				
	Clinical Observation			a :		g: 2	a: a	
				Site	1	Site 2	Site 3	
	Trachea hematoma			0		2	0	
	Death			4		1	0	
	Swollen joints/Arthritis		1		2	0		
	Decreased appetite		15		0	0		
	Dyspnea*			18		0	0	
	Lameness			6)	0	1	
	Depression			1		0	0	
	Ataxia*			1		0	0	
	Abnormal breathing*			2	,	0	0	
	Anorexia			1:	5	0	0	
	Diarrhea			1		0	3	
	Coug	1		0	5			

605 19A5.D3 Page 3 of 4

	Loss of condition	0	11	4		
	Small, unthrifty	0	1	0		
	Umbilical hernia	0	0	2		
	*One pig observed with dyspnea, ataxia and abnormal breathing immediately after vaccination, all of which resolved without medical intervention within a few minutes. All other observations affirmed by licensee to be due to causes other than vaccination.					
USDA Approval Date	August 28, 2019					

605 19A5.D3 Page 4 of 4